Compare Blackrock Inc (BLK) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blackrock Inc vs Neurocrine Biosciences Inc — how do they compare? Blackrock Inc trades at $1,148.83 (market cap $175.22B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Blackrock Inc is far larger — about 10.5× Neurocrine Biosciences Inc's market cap, and Blackrock Inc pays a 2.03% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| BLK | NBIX | |
|---|---|---|
Market Cap | $175.22B | $16.76B |
Volume | 641,547 | — |
Sector | Financials | Health |
52-Week High | $1.20K | $185.50 |
52-Week Low | $922.90 | $123.10 |
Enterprise Value | $176.32B | $16.78B |
Dividend Yield | 2.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BlackRock (BLK) trades at $1,136.39, up 0.63% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with revenue growth from $20.4B in 2024 to $24.2B in 2025, though net income margin compressed to 22.93%. Recent earnings beats and a 78.79% analyst buy rating support positive sentiment, while the stock trades near resistance at $1,144.
BLK presents a compelling investment case with consistent earnings outperformance and strong institutional support, though investors face risks from margin compression and legal scrutiny. The consensus price target of $1,350 suggests 18.8% upside potential, balanced by overbought technical indicators and competitive pressures in asset management.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
